{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,14]],"date-time":"2026-10-14T11:55:47Z","timestamp":1791978947598,"version":"4.4.0"},"reference-count":63,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,6,3]],"date-time":"2026-06-03T00:00:00Z","timestamp":1780444800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,6,3]],"date-time":"2026-06-03T00:00:00Z","timestamp":1780444800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82372354"],"award-info":[{"award-number":["82372354"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82341120"],"award-info":[{"award-number":["82341120"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82501971"],"award-info":[{"award-number":["82501971"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sig Transduct Target Ther"],"DOI":"10.1038\/s41392-026-02680-x","type":"journal-article","created":{"date-parts":[[2026,6,3]],"date-time":"2026-06-03T15:45:18Z","timestamp":1780501518000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Innovative peptide-loaded hybrid membrane nanovaccine enables precise personalized immunotherapy for HPV-related cervical diseases"],"prefix":"10.1038","volume":"11","author":[{"given":"Renjie","family":"Wang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jie","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jinghan","family":"Ruan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chun","family":"Gao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bai","family":"Hu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liang","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bingqing","family":"Liao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ding","family":"Ma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2599-4959","authenticated-orcid":false,"given":"Shuguang","family":"Tan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuanzhen","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shujie","family":"Liao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,6,3]]},"reference":[{"key":"2680_CR1","unstructured":"World Health Organization. Cervical cancer. https:\/\/www.who.int\/news-room\/fact-sheets\/detail\/cervical-cancer (2025). Accessed 20 February 2026."},{"key":"2680_CR2","first-page":"229","volume":"74","author":"F Bray","year":"2024","unstructured":"Bray, F. et al. Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J. Clin. 74, 229\u2013263 (2024).","journal-title":"CA Cancer J. Clin."},{"key":"2680_CR3","doi-asserted-by":"publisher","first-page":"547","DOI":"10.1001\/jama.2023.13174","volume":"330","author":"RB Perkins","year":"2023","unstructured":"Perkins, R. B., Wentzensen, N., Guido, R. S. & Schiffman, M. Cervical cancer screening: a review. JAMA 330, 547\u2013558 (2023).","journal-title":"JAMA"},{"key":"2680_CR4","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1002\/cac2.12629","volume":"45","author":"M Xu","year":"2025","unstructured":"Xu, M., Cao, C., Wu, P., Huang, X. & Ma, D. Advances in cervical cancer: current insights and future directions. Cancer Commun. 45, 77\u2013109 (2025).","journal-title":"Cancer Commun."},{"key":"2680_CR5","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1016\/j.canlet.2021.10.036","volume":"525","author":"S Zhao","year":"2022","unstructured":"Zhao, S. et al. Cervical cancer burden, status of implementation and challenges of cervical cancer screening in Association of Southeast Asian Nations (ASEAN) countries. Cancer Lett. 525, 22\u201332 (2022).","journal-title":"Cancer Lett."},{"key":"2680_CR6","doi-asserted-by":"publisher","first-page":"4953","DOI":"10.1158\/1078-0432.CCR-20-2833","volume":"27","author":"L Ferrall","year":"2021","unstructured":"Ferrall, L., Lin, K. Y., Roden, R. B. S., Hung, C. F. & Wu, T. C. Cervical cancer immunotherapy: facts and hopes. Clin. Cancer Res. 27, 4953\u20134973 (2021).","journal-title":"Clin. Cancer Res."},{"key":"2680_CR7","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1016\/j.critrevonc.2019.02.009","volume":"137","author":"M Liontos","year":"2019","unstructured":"Liontos, M., Kyriazoglou, A., Dimitriadis, I., Dimopoulos, M. A. & Bamias, A. Systemic therapy in cervical cancer: 30 years in review. Crit. Rev. Oncol. Hematol. 137, 9\u201317 (2019).","journal-title":"Crit. Rev. Oncol. Hematol."},{"key":"2680_CR8","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1056\/NEJMra2404457","volume":"392","author":"KS Tewari","year":"2025","unstructured":"Tewari, K. S. Cervical cancer. N. Engl. J. Med. 392, 56\u201371 (2025).","journal-title":"N. Engl. J. Med."},{"key":"2680_CR9","unstructured":"World Health Organization. Global Strategy to Accelerate the Elimination of Cervical Cancer as a Public Health Problem (World Health Organization, 2020)."},{"key":"2680_CR10","doi-asserted-by":"publisher","first-page":"169","DOI":"10.1016\/S0140-6736(18)32470-X","volume":"393","author":"PA Cohen","year":"2019","unstructured":"Cohen, P. A., Jhingran, A., Oaknin, A. & Denny, L. Cervical cancer. Lancet 393, 169\u2013182 (2019).","journal-title":"Lancet"},{"key":"2680_CR11","doi-asserted-by":"publisher","DOI":"10.1007\/s11912-021-01052-8","volume":"23","author":"D Mauricio","year":"2021","unstructured":"Mauricio, D., Zeybek, B., Tymon-Rosario, J., Harold, J. & Santin, A. D. Immunotherapy in cervical cancer. Curr. Oncol. Rep. 23, 61 (2021).","journal-title":"Curr. Oncol. Rep."},{"key":"2680_CR12","doi-asserted-by":"publisher","DOI":"10.1016\/j.ctrv.2022.102385","volume":"106","author":"BJ Monk","year":"2022","unstructured":"Monk, B. J. et al. Integration of immunotherapy into treatment of cervical cancer: recent data and ongoing trials. Cancer Treat. Rev. 106, 102385 (2022).","journal-title":"Cancer Treat. Rev."},{"key":"2680_CR13","doi-asserted-by":"publisher","first-page":"275","DOI":"10.1038\/s41392-024-01983-1","volume":"9","author":"L Yang","year":"2024","unstructured":"Yang, L. et al. Sequential responsive nano-PROTACs for precise intracellular delivery and enhanced degradation efficacy in colorectal cancer therapy. Signal Transduct. Target Ther. 9, 275 (2024).","journal-title":"Signal Transduct. Target Ther."},{"key":"2680_CR14","doi-asserted-by":"publisher","first-page":"djw261","DOI":"10.1093\/jnci\/djw261","volume":"109","author":"JL Gulley","year":"2017","unstructured":"Gulley, J. L. et al. Role of antigen spread and distinctive characteristics of immunotherapy in cancer treatment. J. Natl. Cancer Inst. 109, djw261 (2017).","journal-title":"J. Natl. Cancer Inst."},{"key":"2680_CR15","doi-asserted-by":"publisher","first-page":"88","DOI":"10.1016\/j.canlet.2019.11.039","volume":"471","author":"R Wang","year":"2020","unstructured":"Wang, R. et al. Human papillomavirus vaccine against cervical cancer: opportunity and challenge. Cancer Lett. 471, 88\u2013102 (2020).","journal-title":"Cancer Lett."},{"key":"2680_CR16","doi-asserted-by":"publisher","first-page":"120","DOI":"10.3892\/ijmm.2012.1168","volume":"31","author":"S Liao","year":"2013","unstructured":"Liao, S. et al. HPV16\/18 E5, a promising candidate for cervical cancer vaccines, affects SCPs, cell proliferation and cell cycle, and forms a potential network with E6 and E7. Int. J. Mol. Med. 31, 120\u2013128 (2013).","journal-title":"Int. J. Mol. Med."},{"key":"2680_CR17","doi-asserted-by":"publisher","first-page":"295","DOI":"10.1016\/j.molimm.2014.12.007","volume":"64","author":"S Liao","year":"2015","unstructured":"Liao, S. et al. A novel \u201cpriming-boosting\u201d strategy for immune interventions in cervical cancer. Mol. Immunol. 64, 295\u2013305 (2015).","journal-title":"Mol. Immunol."},{"key":"2680_CR18","doi-asserted-by":"publisher","first-page":"1033","DOI":"10.1126\/science.aat7171","volume":"361","author":"JG Reiter","year":"2018","unstructured":"Reiter, J. G. et al. Minimal functional driver gene heterogeneity among untreated metastases. Science 361, 1033\u20131037 (2018).","journal-title":"Science"},{"key":"2680_CR19","doi-asserted-by":"publisher","first-page":"68","DOI":"10.3892\/ijo.2023.5516","volume":"62","author":"DH Liu","year":"2023","unstructured":"Liu, D. H., Mou, F. F., An, M. & Xia, P. Human leukocyte antigen and tumor immunotherapy (Review). Int. J. Oncol. 62, 68 (2023).","journal-title":"Int. J. Oncol."},{"key":"2680_CR20","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.aao5931","volume":"10","author":"JL Tanyi","year":"2018","unstructured":"Tanyi, J. L. et al. Personalized cancer vaccine effectively mobilizes antitumor T cell immunity in ovarian cancer. Sci. Transl. Med. 10, eaao5931 (2018).","journal-title":"Sci. Transl. Med."},{"key":"2680_CR21","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1016\/j.jocn.2020.03.006","volume":"74","author":"JD Rudnick","year":"2020","unstructured":"Rudnick, J. D. et al. A phase I trial of surgical resection with Gliadel Wafer placement followed by vaccination with dendritic cells pulsed with tumor lysate for patients with malignant glioma. J. Clin. Neurosci. 74, 187\u2013193 (2020).","journal-title":"J. Clin. Neurosci."},{"key":"2680_CR22","doi-asserted-by":"publisher","first-page":"1044","DOI":"10.1016\/j.cell.2020.02.041","volume":"180","author":"KA Fitzgerald","year":"2020","unstructured":"Fitzgerald, K. A. & Kagan, J. C. Toll-like receptors and the control of immunity. Cell 180, 1044\u20131066 (2020).","journal-title":"Cell"},{"key":"2680_CR23","doi-asserted-by":"publisher","first-page":"375","DOI":"10.1038\/nri3837","volume":"15","author":"M Kaparakis-Liaskos","year":"2015","unstructured":"Kaparakis-Liaskos, M. & Ferrero, R. L. Immune modulation by bacterial outer membrane vesicles. Nat. Rev. Immunol. 15, 375\u2013387 (2015).","journal-title":"Nat. Rev. Immunol."},{"key":"2680_CR24","doi-asserted-by":"publisher","first-page":"360","DOI":"10.1038\/s41568-021-00346-0","volume":"21","author":"M Saxena","year":"2021","unstructured":"Saxena, M., van der Burg, S. H., Melief, C. J. M. & Bhardwaj, N. Therapeutic cancer vaccines. Nat. Rev. Cancer 21, 360\u2013378 (2021).","journal-title":"Nat. Rev. Cancer"},{"key":"2680_CR25","doi-asserted-by":"publisher","first-page":"8609","DOI":"10.1021\/acs.nanolett.1c02482","volume":"21","author":"MZ Zou","year":"2021","unstructured":"Zou, M. Z., Li, Z. H., Bai, X. F., Liu, C. J. & Zhang, X. Z. Hybrid vesicles based on autologous tumor cell membrane and bacterial outer membrane to enhance innate immune response and personalized tumor immunotherapy. Nano Lett. 21, 8609\u20138618 (2021).","journal-title":"Nano Lett."},{"key":"2680_CR26","doi-asserted-by":"publisher","DOI":"10.1186\/s12951-022-01429-2","volume":"20","author":"Y Ding","year":"2022","unstructured":"Ding, Y. et al. Application of lipid nanovesicle drug delivery system in cancer immunotherapy. J. Nanobiotechnology 20, 214 (2022).","journal-title":"J. Nanobiotechnology"},{"key":"2680_CR27","doi-asserted-by":"publisher","first-page":"1384","DOI":"10.1016\/j.vaccine.2019.12.005","volume":"38","author":"E Pastural","year":"2020","unstructured":"Pastural, E. et al. Safety and immunogenicity of a 30-valent M protein-based group a streptococcal vaccine in healthy adult volunteers: a randomized, controlled phase I study. Vaccine 38, 1384\u20131392 (2020).","journal-title":"Vaccine"},{"key":"2680_CR28","doi-asserted-by":"publisher","DOI":"10.1002\/advs.202102330","volume":"8","author":"Y Yang","year":"2021","unstructured":"Yang, Y., Wang, K., Pan, Y., Rao, L. & Luo, G. Engineered cell membrane-derived nanoparticles in immune modulation. Adv. Sci. 8, e2102330 (2021).","journal-title":"Adv. Sci."},{"key":"2680_CR29","doi-asserted-by":"publisher","DOI":"10.1002\/adma.201808200","volume":"31","author":"H Min","year":"2019","unstructured":"Min, H. et al. Biomimetic metal-organic framework nanoparticles for cooperative combination of antiangiogenesis and photodynamic therapy for enhanced efficacy. Adv. Mater. 31, e1808200 (2019).","journal-title":"Adv. Mater."},{"key":"2680_CR30","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.abc2816","volume":"13","author":"L Chen","year":"2021","unstructured":"Chen, L. et al. Bacterial cytoplasmic membranes synergistically enhance the antitumor activity of autologous cancer vaccines. Sci. Transl. Med. 13, eabc2816 (2021).","journal-title":"Sci. Transl. Med."},{"key":"2680_CR31","doi-asserted-by":"publisher","first-page":"1301","DOI":"10.1158\/2326-6066.CIR-18-0166","volume":"6","author":"G Galliverti","year":"2018","unstructured":"Galliverti, G. et al. Nanoparticle conjugation of human papillomavirus 16 E7-long peptides enhances therapeutic vaccine efficacy against solid tumors in mice. Cancer Immunol. Res. 6, 1301\u20131313 (2018).","journal-title":"Cancer Immunol. Res."},{"key":"2680_CR32","doi-asserted-by":"publisher","first-page":"8281","DOI":"10.1016\/j.biomaterials.2011.07.032","volume":"32","author":"H Wang","year":"2011","unstructured":"Wang, H. et al. Enhanced anti-tumor efficacy by co-delivery of doxorubicin and paclitaxel with amphiphilic methoxy PEG-PLGA copolymer nanoparticles. Biomaterials 32, 8281\u20138290 (2011).","journal-title":"Biomaterials"},{"key":"2680_CR33","doi-asserted-by":"publisher","DOI":"10.1186\/s12951-024-02812-x","volume":"22","author":"W Kong","year":"2024","unstructured":"Kong, W. et al. Role of size, surface charge, and PEGylated lipids of lipid nanoparticles (LNPs) on intramuscular delivery of mRNA. J. Nanobiotechnology 22, 553 (2024).","journal-title":"J. Nanobiotechnology"},{"key":"2680_CR34","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1038\/cr.2016.157","volume":"27","author":"RL Sabado","year":"2017","unstructured":"Sabado, R. L., Balan, S. & Bhardwaj, N. Dendritic cell-based immunotherapy. Cell Res. 27, 74\u201395 (2017).","journal-title":"Cell Res."},{"key":"2680_CR35","doi-asserted-by":"publisher","first-page":"2240","DOI":"10.1038\/s41596-022-00713-7","volume":"17","author":"X Zhao","year":"2022","unstructured":"Zhao, X., Zhao, R. & Nie, G. Nanocarriers based on bacterial membrane materials for cancer vaccine delivery. Nat. Protoc. 17, 2240\u20132274 (2022).","journal-title":"Nat. Protoc."},{"key":"2680_CR36","doi-asserted-by":"publisher","DOI":"10.1002\/EXP.20230171","volume":"4","author":"M Yang","year":"2024","unstructured":"Yang, M. et al. Tumor cell membrane-based vaccines: a potential boost for cancer immunotherapy. Exploration 4, 20230171 (2024).","journal-title":"Exploration"},{"key":"2680_CR37","doi-asserted-by":"publisher","first-page":"5708","DOI":"10.1021\/acsnano.5c17200","volume":"20","author":"JX An","year":"2026","unstructured":"An, J. X., Tang, Y., He, J., Qin, Y. T. & Zhang, X. Z. An intracellular gelated macrophage-based vaccine for tumor immunotherapy. ACS Nano 20, 5708\u20135719 (2026).","journal-title":"ACS Nano"},{"key":"2680_CR38","doi-asserted-by":"publisher","first-page":"1164","DOI":"10.1158\/2159-8290.CD-21-0502","volume":"13","author":"MH Linde","year":"2023","unstructured":"Linde, M. H. et al. Reprogramming cancer into antigen-presenting cells as a novel immunotherapy. Cancer Discov. 13, 1164\u20131185 (2023).","journal-title":"Cancer Discov."},{"key":"2680_CR39","doi-asserted-by":"publisher","first-page":"2030","DOI":"10.1001\/jama.2023.21987","volume":"330","author":"RA Voelker","year":"2023","unstructured":"Voelker, R. A. Cervical cancer screening. JAMA 330, 2030 (2023).","journal-title":"JAMA"},{"key":"2680_CR40","doi-asserted-by":"publisher","first-page":"104","DOI":"10.1186\/s13045-022-01322-3","volume":"15","author":"Y Yan","year":"2022","unstructured":"Yan, Y. et al. Metabolic profiles of regulatory T cells and their adaptations to the tumor microenvironment: implications for antitumor immunity. J. Hematol. Oncol. 15, 104 (2022).","journal-title":"J. Hematol. Oncol."},{"key":"2680_CR41","doi-asserted-by":"publisher","DOI":"10.1016\/j.ebiom.2023.104612","volume":"92","author":"T Zhang","year":"2023","unstructured":"Zhang, T. et al. Identification of cervical cancer stem cells using single-cell transcriptomes of normal cervix, cervical premalignant lesions, and cervical cancer. EBioMedicine 92, 104612 (2023).","journal-title":"EBioMedicine"},{"key":"2680_CR42","doi-asserted-by":"publisher","DOI":"10.1002\/advs.202302340","volume":"11","author":"B Hu","year":"2024","unstructured":"Hu, B. et al. A promising new model: establishment of patient-derived organoid models covering HPV-related cervical pre-cancerous lesions and their cancers. Adv. Sci. 11, e2302340 (2024).","journal-title":"Adv. Sci."},{"key":"2680_CR43","doi-asserted-by":"publisher","first-page":"4431","DOI":"10.1158\/1078-0432.CCR-14-3341","volume":"21","author":"LM Draper","year":"2015","unstructured":"Draper, L. M. et al. Targeting of HPV-16+ epithelial cancer cells by TCR gene engineered T cells directed against E6. Clin. Cancer Res. 21, 4431\u20134439 (2015).","journal-title":"Clin. Cancer Res."},{"key":"2680_CR44","doi-asserted-by":"publisher","DOI":"10.1172\/jci.insight.99488","volume":"3","author":"BY Jin","year":"2018","unstructured":"Jin, B. Y. et al. Engineered T cells targeting E7 mediate regression of human papillomavirus cancers in a murine model. JCI Insight 3, e99488 (2018).","journal-title":"JCI Insight"},{"key":"2680_CR45","doi-asserted-by":"publisher","first-page":"2473","DOI":"10.4049\/jimmunol.156.7.2473","volume":"156","author":"MH Newberg","year":"1996","unstructured":"Newberg, M. H. et al. Importance of MHC class 1 alpha2 and alpha3 domains in the recognition of self and non-self MHC molecules. J. Immunol. 156, 2473\u20132480 (1996).","journal-title":"J. Immunol."},{"key":"2680_CR46","doi-asserted-by":"publisher","first-page":"182","DOI":"10.1038\/s41571-024-00977-w","volume":"22","author":"AA Francoeur","year":"2025","unstructured":"Francoeur, A. A., Monk, B. J. & Tewari, K. S. Treatment advances across the cervical cancer spectrum. Nat. Rev. Clin. Oncol. 22, 182\u2013199 (2025).","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"2680_CR47","doi-asserted-by":"publisher","first-page":"a000414","DOI":"10.1101\/cshperspect.a000414","volume":"2","author":"TJ Silhavy","year":"2010","unstructured":"Silhavy, T. J., Kahne, D. & Walker, S. The bacterial cell envelope. Cold Spring Harb. Perspect. Biol. 2, a000414 (2010).","journal-title":"Cold Spring Harb. Perspect. Biol."},{"key":"2680_CR48","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1016\/j.clim.2008.08.016","volume":"130","author":"HR Jang","year":"2009","unstructured":"Jang, H. R. & Rabb, H. The innate immune response in ischemic acute kidney injury. Clin. Immunol. 130, 41\u201350 (2009).","journal-title":"Clin. Immunol."},{"key":"2680_CR49","first-page":"47","volume":"4","author":"B Han","year":"2024","unstructured":"Han, B. et al. Cancer incidence and mortality in China, 2022. J. Natl. Cancer Cent. 4, 47\u201353 (2024).","journal-title":"J. Natl. Cancer Cent."},{"key":"2680_CR50","doi-asserted-by":"publisher","first-page":"e070115","DOI":"10.1136\/bmj-2022-070115","volume":"379","author":"L Rahangdale","year":"2022","unstructured":"Rahangdale, L., Mungo, C., O\u2019Connor, S., Chibwesha, C. J. & Brewer, N. T. Human papillomavirus vaccination and cervical cancer risk. BMJ 379, e070115 (2022).","journal-title":"BMJ"},{"key":"2680_CR51","doi-asserted-by":"publisher","first-page":"1170","DOI":"10.1016\/j.ccell.2023.05.009","volume":"41","author":"C Vennin","year":"2023","unstructured":"Vennin, C. et al. Taxanes trigger cancer cell killing in vivo by inducing non-canonical T cell cytotoxicity. Cancer Cell 41, 1170\u20131185.e1112 (2023).","journal-title":"Cancer Cell"},{"key":"2680_CR52","doi-asserted-by":"publisher","first-page":"120","DOI":"10.1038\/s41586-020-2746-2","volume":"586","author":"KA Lawson","year":"2020","unstructured":"Lawson, K. A. et al. Functional genomic landscape of cancer-intrinsic evasion of killing by T cells. Nature 586, 120\u2013126 (2020).","journal-title":"Nature"},{"key":"2680_CR53","doi-asserted-by":"publisher","DOI":"10.1126\/sciadv.aaw6870","volume":"5","author":"X Han","year":"2019","unstructured":"Han, X. et al. Red blood cell-derived nanoerythrosome for antigen delivery with enhanced cancer immunotherapy. Sci. Adv. 5, eaaw6870 (2019).","journal-title":"Sci. Adv."},{"key":"2680_CR54","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-019-11157-1","volume":"10","author":"WL Liu","year":"2019","unstructured":"Liu, W. L. et al. Cytomembrane nanovaccines show therapeutic effects by mimicking tumor cells and antigen presenting cells. Nat. Commun. 10, 3199 (2019).","journal-title":"Nat. Commun."},{"key":"2680_CR55","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1002\/(SICI)1097-0215(19980925)78:1<41::AID-IJC8>3.0.CO;2-X","volume":"78","author":"H Ji","year":"1998","unstructured":"Ji, H. et al. Antigen-specific immunotherapy for murine lung metastatic tumors expressing human papillomavirus type 16 E7 oncoprotein. Int. J. Cancer 78, 41\u201345 (1998).","journal-title":"Int. J. Cancer"},{"key":"2680_CR56","doi-asserted-by":"publisher","DOI":"10.1002\/smll.202007165","volume":"17","author":"X He","year":"2021","unstructured":"He, X. et al. HPV-associated tumor eradication by vaccination with synthetic short peptides and particle-forming liposomes. Small 17, e2007165 (2021).","journal-title":"Small"},{"key":"2680_CR57","doi-asserted-by":"publisher","first-page":"351","DOI":"10.1038\/nrc2373","volume":"8","author":"CJ Melief","year":"2008","unstructured":"Melief, C. J. & van der Burg, S. H. Immunotherapy of established (pre)malignant disease by synthetic long peptide vaccines. Nat. Rev. Cancer 8, 351\u2013360 (2008).","journal-title":"Nat. Rev. Cancer"},{"key":"2680_CR58","doi-asserted-by":"publisher","first-page":"6011","DOI":"10.7150\/thno.38742","volume":"10","author":"X Chen","year":"2020","unstructured":"Chen, X., Yang, J., Wang, L. & Liu, B. Personalized neoantigen vaccination with synthetic long peptides: recent advances and future perspectives. Theranostics 10, 6011\u20136023 (2020).","journal-title":"Theranostics"},{"key":"2680_CR59","doi-asserted-by":"publisher","first-page":"175","DOI":"10.1038\/s41573-018-0006-z","volume":"18","author":"RS Riley","year":"2019","unstructured":"Riley, R. S., June, C. H., Langer, R. & Mitchell, M. J. Delivery technologies for cancer immunotherapy. Nat. Rev. Drug Discov. 18, 175\u2013196 (2019).","journal-title":"Nat. Rev. Drug Discov."},{"key":"2680_CR60","doi-asserted-by":"publisher","first-page":"227","DOI":"10.1038\/s41392-025-02280-1","volume":"10","author":"M Tufail","year":"2025","unstructured":"Tufail, M., Jiang, C. H. & Li, N. Immune evasion in cancer: mechanisms and cutting-edge therapeutic approaches. Signal Transduct. Target Ther. 10, 227 (2025).","journal-title":"Signal Transduct. Target Ther."},{"key":"2680_CR61","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1186\/s13045-021-01056-8","volume":"14","author":"JA Marin-Acevedo","year":"2021","unstructured":"Marin-Acevedo, J. A., Kimbrough, E. O. & Lou, Y. Next generation of immune checkpoint inhibitors and beyond. J. Hematol. Oncol. 14, 45 (2021).","journal-title":"J. Hematol. Oncol."},{"key":"2680_CR62","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.ab.2016.10.025","volume":"518","author":"JE Guzman-Flores","year":"2017","unstructured":"Guzman-Flores, J. E., Alvarez, A. F., Poggio, S., Gavilanes-Ruiz, M. & Georgellis, D. Isolation of detergent-resistant membranes (DRMs) from Escherichia coli. Anal. Biochem. 518, 1\u20138 (2017).","journal-title":"Anal. Biochem."},{"key":"2680_CR63","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-023-42010-1","volume":"14","author":"D Lu","year":"2023","unstructured":"Lu, D. et al. KRAS G12V neoantigen specific T cell receptor for adoptive T cell therapy against tumors. Nat. Commun. 14, 6389 (2023).","journal-title":"Nat. Commun."}],"container-title":["Signal Transduction and Targeted Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41392-026-02680-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41392-026-02680-x","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41392-026-02680-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,3]],"date-time":"2026-06-03T17:02:46Z","timestamp":1780506166000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41392-026-02680-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,3]]},"references-count":63,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["2680"],"URL":"https:\/\/doi.org\/10.1038\/s41392-026-02680-x","relation":{},"ISSN":["2059-3635"],"issn-type":[{"value":"2059-3635","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,3]]},"assertion":[{"value":"31 March 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 February 2026","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 March 2026","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 June 2026","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"214"}}